Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

Abstract

PD-L1 on the surface of tumor cells binds its receptor PD-1 on effector T cells, thereby suppressing their activity. Antibody blockade of PD-L1 can activate an anti-tumor immune response leading to durable remissions in a subset of cancer patients. Here, we describe an alternative mechanism of PD-L1 activity involving its secretion in tumor-derived exosomes. Removal of exosomal PD-L1 inhibits tumor growth, even in models resistant to anti-PD-L1 antibodies. Exosomal PD-L1 from the tumor suppresses T cell activation in the draining lymph node. Systemically introduced exosomal PD-L1 rescues growth of tumors unable to secrete their own. Exposure to exosomal PD-L1-deficient tumor cells suppresses growth of wild-type tumor cells injected at a distant site, simultaneously or months later. Anti-PD-L1 antibodies work additively, not redundantly, with exosomal PD-L1 blockade to suppress tumor growth. Together, these findings show that exosomal PD-L1 represents an unexplored therapeutic target, which could overcome resistance to current antibody approaches.

References 54

1. 1.

   Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, and Min WP (2005 ). Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol. Dis 35, 169–173.

   Not in our library10.1016/j.bcmd.2005.07.001

2. 2.

   Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S, (2017 ). CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 549, 101–105.

   Not in our library10.1038/nature23643

3. 3.

   Carr B, and Warren J (2012 ). Company profile: NanoSight: delivering practical solutions for biological nanotechnology. Nanomedicine (Lond.) 7, 1129–1132.

   Not in our library10.2217/nnm.12.43

4. 4.

   Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, and Felsher DW (2016 ). MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227–231.

   Not in our library10.1126/science.aac9935

5. 5.

   Chassé H, Boulben S, Costache V, Cormier P, and Morales J (2017 ). Analysis of translation using polysome profiling. Nucleic Acids Res. 45, e15.

   Not in our library10.1093/nar/gkw907

6. 6.

   Chen DS, and Mellman I (2013 ). Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10.

   Not in our library10.1016/j.immuni.2013.07.012

7. 7.

   Chen DS, and Mellman I (2017 ). Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330.

   Not in our library10.1038/nature21349

8. 8.

   Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, (2018 ). Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560, 382–386.

   Not in our library10.1038/s41586-018-0392-8

9. 9.

   Ciechanover A (2005 ). Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat. Rev. Mol. Cell Biol. 6, 79–87.

   Not in our library10.1038/nrm1552

10. 10.

    Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, and Fu YX (2014 ). Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest 124, 687–695.

    Not in our library10.1172/jci67313

11. 11.

    Faustino-Rocha A, Oliveira PA, Pinho-Oliveira J, Teixeira-Guedes C, Soares-Maia R, da Costa RG, Colaço B, Pires MJ, Colaço J, Ferreira R, and Ginja M (2013 ). Estimation of rat mammary tumor volume using caliper and ultrasonography measurements. Lab Anim. (NY) 42, 217–224.

    Not in our library10.1038/laban.254

12. 12.

    Fong MY, Zhou W, Liu L, Alontaga AY, Chandra M, Ashby J, Chow A, O’Connor ST, Li S, Chin AR, (2015 ). Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 17, 183–194.

    Not in our library10.1038/ncb3094

13. 13.

    Foster BA, Gingrich JR, Kwon ED, Madias C, and Greenberg NM (1997 ). Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 57, 3325–3330.

    Not in our library

14. 14.

    Francisco LM, Sage PT, and Sharpe AH (2010 ). The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev 236, 219–242.

    Not in our library10.1111/j.1600-065x.2010.00923.x

15. 15.

    Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, (2017 ). Interferon receptor signaling pathways regulating PD-L1 and PD-L2 Expression. Cell Rep. 19, 1189–1201.

    Not in our library10.1016/j.celrep.2017.04.031

16. 16.

    Goswami S, Aparicio A, and Subudhi SK (2016 ). Immune checkpoint therapies in prostate cancer. Cancer J. 22, 117–120.

    Not in our library10.1097/ppo.0000000000000176

17. 17.

    Hood JL, San RS, and Wickline SA (2011 ). Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 71, 3792–3801.

    Not in our library10.1158/0008-5472.can-10-4455

18. 18.

    Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, (2015 ). Tumour exosome integrins determine organotropic metastasis. Nature 527, 329–335.

    Not in our library10.1038/nature15756

19. 19.

    Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I, and Vale RD (2017 ). T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 355, 1428–1433.

    Not in our library10.1126/science.aaf1292

20. 20.

    Johnson JL, Ramadass M, He J, Brown SJ, Zhang J, Abgaryan L, Biris N, Gavathiotis E, Rosen H, and Catz SD (2016 ). Identification of neutrophil exocytosis inhibitors (Nexinhibs), small molecule inhibitors of neutrophil exocytosis and inflammation: druggability of the small GTPase Rab27a. J. Biol. Chem 291, 25965–25982.

    Not in our library10.1074/jbc.m116.741884

21. 21.

    Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, and Ochiya T (2010 ). Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem 285, 17442–17452.

    Not in our library10.1074/jbc.m110.107821

22. 22.

    Lee DH, and Goldberg AL (1998 ). Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8, 397–403.

    Not in our library10.1016/s0962-8924(98)01346-4

23. 23.
    Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity · 2016

    No notice
24. 24.

    Liu C, Yu S, Zinn K, Wang J, Zhang L, Jia Y, Kappes JC, Barnes S, Kimberly RP, Grizzle WE, and Zhang HG (2006 ). Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function.J. Immunol 176, 1375–1385.

    Not in our library10.4049/jimmunol.176.3.1375

25. 25.

    Luberto C, Hassler DF, Signorelli P, Okamoto Y, Sawai H, Boros E, Hazen-Martin DJ, Obeid LM, Hannun YA, and Smith GK (2002 ). Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J. Biol. Chem 277, 41128–41139.

    Not in our library10.1074/jbc.m206747200

26. 26.

    Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, Meeker AK, Lucia MS, Anders RA, DeMarzo AM, and Drake CG (2015 ). Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 18, 325–332.

    Not in our library10.1038/pcan.2015.39

27. 27.

    Mauvezin C, and Neufeld TP (2015 ). Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome fusion. Autophagy 11, 1437–1438.

    Not in our library10.1080/15548627.2015.1066957

28. 28.

    Mellman I, Coukos G, and Dranoff G (2011 ). Cancer immunotherapy comes of age. Nature 480, 480–489.

    Not in our library10.1038/nature10673

29. 29.

    Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, Logtenberg MEW, Slagter M, Rozeman EA, Hofland I, (2017 ). Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 549, 106–110.

    Not in our library10.1038/nature23669

30. 30.

    Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, and Formenti SC (2018 ). Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer 18, 313–322.

    Not in our library10.1038/nrc.2018.6

31. 31.

    Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A, Moita CF, Schauer K, Hume AN, Freitas RP, (2010 ). Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol 12, 19–30, sup pp 11–13.

    Not in our library10.1038/ncb2000

32. 32.

    Page DB, Postow MA, Callahan MK, Allison JP, and Wolchok JD (2014 ). Immune modulation in cancer with antibodies. Annu. Rev. Med 65, 185–202.

    Not in our library10.1146/annurev-med-092012-112807

33. 33.

    Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar C, (2012 ). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med 18, 883–891.

    Not in our library10.1038/nm.2753

34. 34.

    Phuyal S, Hessvik NP, Skotland T, Sandvig K, and Llorente A (2014 ). Regulation of exosome release by glycosphingolipids and flotillins. FEBS J. 281, 2214–2227.

    Not in our library10.1111/febs.12775

35. 35.

    Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, and Zhang F (2013 ). Genome engineering using the CRISPR-Cas9 system. Nat. Protoc 8, 2281–2308.

    Not in our library10.1038/nprot.2013.143

36. 36.

    Ricklefs FL, Alayo Q, Krenzlin H, Mahmoud AB, Speranza MC, Nakashima H, Hayes JL, Lee K, Balaj L, Passaro C, (2018 ). Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv 4, eaar2766.

    Not in our library10.1126/sciadv.aar2766

37. 37.

    Ruivo CF, Adem B, Silva M, and Melo SA (2017 ). The biology of cancer exosomes: insights and new perspectives. Cancer Res. 77, 6480–6488.

    Not in our library10.1158/0008-5472.can-17-0994

38. 38.

    Sharma P, Hu-Lieskovan S, Wargo JA, and Ribas A (2017 ). Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723.

    Not in our library10.1016/j.cell.2017.01.017

39. 39.
    Y-box protein 1 is required to sort microRNAs into exosomes in cells and in a cell-free reaction · 2016

    No notice
40. 40.

    Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr., Carter BS, Krichevsky AM, and Breakefield XO (2008 ). Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10, 1470–1476.

    Not in our library10.1038/ncb1800

41. 41.

    Stanley P (2011 ). Golgi glycosylation. Cold Spring Harb. Perspect. Biol 3, a005199.

    Not in our library10.1101/cshperspect.a005199

42. 42.
    Directional cell movement through tissues is controlled by exosome secretion · 2015

    No notice
43. 43.

    Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, and White-side TL (2018 ). Clinical significance of PD-L1+ exosomes in plasma of head and neck cancer patients. Clin. Cancer Res. 24, 896–905.

    Not in our library10.1158/1078-0432.ccr-17-2664

44. 44.
    Why the need and how to approach the functional diversity of extracellular vesicles · 2017

    No notice
45. 45.

    Topalian SL, Drake CG, and Pardoll DM (2015 ). Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461.

    Not in our library10.1016/j.ccell.2015.03.001

46. 46.

    van Niel G, D’Angelo G, and Raposo G (2018 ). Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213–228.

    Not in our library10.1038/nrm.2017.125

47. 47.

    Wolfers J, Lozier A, Raposo G, Regnault A, Théry C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, (2001 ). Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med 7, 297–303.

    Not in our library10.1038/85438

48. 48.

    Xu R, Greening DW, Zhu HJ, Takahashi N, and Simpson RJ (2016 ). Extracellular vesicle isolation and characterization: toward clinical application.J. Clin. Invest 126, 1152–1162.

    Not in our library10.1172/jci81129

49. 49.

    Yang Y, Li CW, Chan LC, Wei Y, Hsu JM, Xia W, Cha JH, Hou J, Hsu JL, Sun L, and Hung MC (2018 ). Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res. 28, 862–864.

    Not in our library10.1038/s41422-018-0060-4

50. 50.

    Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, and Saito T (2012 ). Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med 209, 1201–1217.

    Not in our library10.1084/jem.20112741

51. 51.

    Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L, Li C, Cong Y, Kimberly R, Grizzle WE, (2007 ). Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J. Immunol 178, 6867–6875.

    Not in our library10.4049/jimmunol.178.11.6867

52. 52.

    Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, and Waldmann TA (2012 ). Simultaneous inhibition of two regulatory T-cell subsets enhanced interleukin-15 efficacy in a prostate tumor model. Proc. Natl. Acad. Sci. USA 109, 6187–6192.

    Not in our library10.1073/pnas.1203479109

53. 53.

    Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, East-ham JA, Scardino PT, Sharma P, and Allison JP (2007 ). B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc. Natl. Acad. Sci. USA 104, 19458–19463.

    Not in our library10.1073/pnas.0709802104

54. 54.

    Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O’Connor ST, Chin AR, (2014 ). Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 25, 501–515.

    Not in our library10.1016/j.ccr.2014.03.007

Cited by papers we hold 45

• Advances in the regulation of macrophage polarization by the tumor microenvironment · 2025
  Not checked
• Extracellular vesicles as tools and targets in therapy for diseases · 2024
  No notice
• Extracellular vesicles, RNA sequencing, and bioinformatic analyses: Challenges, solutions, and recommendations · 2024
  No notice
• Role of tumor microenvironment in cancer progression and therapeutic strategy · 2023
  No notice
• Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy · 2023
  No notice
• Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors · 2022
  Not checked
• Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer · 2022
  Not checked
• A shared, stochastic pathway mediates exosome protein budding along plasma and endosome membranes · 2022
  No notice
• Recent advances in overcoming barriers to cell‐based delivery systems for cancer immunotherapy · 2022
  No notice
• Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications · 2022
  No notice
• Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer · 2022
  No notice
• LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer · 2022
  No notice
• EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1 · 2022
  No notice
• Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape · 2022
  No notice
• Breast cancer cell-derived extracellular vesicles promote CD8+ T cell exhaustion via TGF-β type II receptor signaling · 2022
  No notice
• Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2 · 2022
  No notice
• Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer · 2022
  No notice
• Dissecting exosome inhibitors: therapeutic insights into small-molecule chemicals against cancer · 2022
  No notice
• Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer · 2022
  No notice
• Neddylation of Coro1a determines the fate of multivesicular bodies and biogenesis of extracellular vesicles · 2021
  Not checked

and 25 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.